{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:21:32Z","timestamp":1791321692881,"version":"4.3.1"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Omadacycline was tested against 21,000 bacterial isolates collected prospectively from medical centers in Europe and the United States during 2016. Omadacycline was active against\n Staphylococcus aureus<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.12\/0.25 mg\/liter), including methicillin-resistant\n S. aureus<\/jats:named-content>\n (MRSA); streptococci (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.06\/0.12 mg\/liter), including\n Streptococcus pneumoniae<\/jats:named-content>\n , viridans group streptococci, and beta-hemolytic streptococci;\n Enterobacteriaceae<\/jats:named-content>\n , including\n Escherichia coli<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.5\/2 mg\/liter);\n Haemophilus influenzae<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 1\/1 mg\/liter); and\n Moraxella catarrhalis<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.25\/0.25 mg\/liter). Omadacycline merits further study in serious infections where resistant pathogens may be encountered.\n <\/jats:p>","DOI":"10.1128\/aac.02327-17","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T12:27:34Z","timestamp":1517315254000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":64,"title":["Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program"],"prefix":"10.1128","volume":"62","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_3_7_2","volume-title":"Abstr 630","author":"O'Riordan WA","year":"2017","unstructured":"O'Riordan WA, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das A, Tzanis E, Eckberg P, Manley A, Villano S, Steenbergen J, Loh E. 2017. A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study). Abstr 630. 27th Eur Congr Clin Microbiol Infect Dis (ECCMID), Vienna, Austria, 22 to 25 April 2017."},{"key":"e_1_3_3_8_2","volume-title":"Paratek announces phase 3 study of oral-only dosing of omadacycline met all primary and secondary FDA and EMA efficacy endpoints in acute bacterial skin infections","author":"Paratek","year":"2017","unstructured":"Paratek. 2017. Paratek announces phase 3 study of oral-only dosing of omadacycline met all primary and secondary FDA and EMA efficacy endpoints in acute bacterial skin infections. Paratek, Boston, MA. https:\/\/globenewswire.com\/news-release\/2017\/07\/17\/1047604\/0\/en\/Paratek-Announces-Phase-3-Study-of-Oral-Only-Dosing-of-Omadacycline-Met-All-Primary-and-Secondary-FDA-and-EMA-Efficacy-Endpoints-in-Acute-Bacterial-Skin-Infections.html. Accessed October 2017."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1413"},{"key":"e_1_3_3_10_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_11_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 27th informational supplement","author":"CLSI","year":"2017","unstructured":"CLSI. 2017. M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_12_2","unstructured":"EUCAST. March 2017. Breakpoint tables for interpretation of MIC's and zone diameters version 7.1. EUCAST. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf. Accessed March 2017."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02327-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02327-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:14:20Z","timestamp":1645478060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02327-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.02327-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02327-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-11-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02327-17"}}